The latest development of antihypertensive medication

1st International Conference on Tropical Medicine and Infectious Diseases (ICTROMI) Faculty of Medicine Universitas Sumatera Utara

Nasution, S.^1 ; Rey, I.^2 ; Effendi-Ys, R.^2

Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, H. Adam Malik General Hospital, Medan, Indonesia^1

Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, H. Adam Malik General Hospital, Medan, Indonesia^2

关键词: Aldosterone synthase;    Cardio-vascular disease;    Drug monitoring;    Epoxide hydrolases;    Latest development;    Mineralocorticoid receptors;    Natriuretic peptides;    Vasoactive intestinal peptide;   

Others  :  https://iopscience.iop.org/article/10.1088/1755-1315/125/1/012106/pdf
DOI  :  10.1088/1755-1315/125/1/012106

来源: IOP

【 摘 要 】

Hypertension is the most common risk factor for cardiovascular disease, stroke, renal failure, and death. Recent drug monitoring studies found non-adherence to BP lowering therapy in 25% to 65% of patients with apparent treatment-resistant hypertension (TRH). This review focuses on the latest development of antihypertensive medication, such as vasopeptidase inhibitors, aldosterone synthase inhibitors, Soluble Epoxide Hydrolase Inhibitors, agonists of natriuretic peptide receptor, Vasoactive Intestinal Peptide Receptor Agonist, a novel mineralocorticoid receptor antagonist, inhibitors of aminopeptidase A, dopamine β-hydroxylase inhibitor, intestinal Na+/H+ exchanger 3 inhibitor and other agents.